The PCR-based technology platform differentiates between samples containing methicillin resistant Staphylococcus aureus (MRSA), methicillin sensitive S. aureus (MSSA) and mixed populations of bacteria by amplifying and evaluating multiple gene targets.
MDI’s Detect-Ready MRSA Panel is a qualitative real-time PCR in vitro diagnostic test that is marketed in the European Union and Australia and is in late-stage development in the US.
The panel’s CE-mark label was recently expanded to include the detection of colonization with MSSA and other bacteria, in addition to MRSA.
MDI CEO and chairman Todd Wallach said the allowance includes broad method and kit claims, and they expect that the issued patent will serve as a resource in their drive to achieve leadership in the molecular detection of resistant pathogens.
